NCT03992716终止4 期
Reaching Protein Target With SmofKabiven® Extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Critical Illness
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 3
- 主要终点
- Proportion of patients reaching ≥70% of the cumulative target for protein delivery from Study Day 2 through Study Day 6
研究概览
简要总结
The main focus of the study is to show that SmofKabiven® extra Nitrogen, in a realistic clinical setting, enables to meet high protein requirements in patients during the first week after onset of critical illness, without risk of overfeeding with energy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years and <90 years, male and female
- •Critically ill, medical or surgical ICU patient
- •Admitted to the ICU on the same day or the day before with a minimum expected ICU stay of 3 days
- •Central venous access available for continuous infusion of the study drugs
- •Sequential Organ Failure Assessment (SOFA) score ≥2
- •Contraindication against enteral nutrition or limited tolerance to enteral nutrition and it is planned that patient receives ≥80% of the total target caloric intake from parenteral nutrition during the first 3 nutritional treatment days
- •Written informed consent from the patient or the patient's legal representative or deferred written consent from the patient or patient's legal representative (deferred proxy consent)
排除标准
- •Contraindication against parenteral nutrition or inability to receive parenteral nutrition via central venous access
- •Received parenteral nutrition within 7 days before randomisation
- •It is planned that patient receives ≥20% of the total target caloric intake via enteral or oral nutrition and/or non-nutritional sources (glucose solution for drug dilution or lipids from propofol/clevidipine or citrate from continuous renal replacement therapy) during the first 3 nutritional treatment days
- •Body mass index (BMI) <18.5 kg/m2 or >35 kg/m2
- •Burn injury
- •Any severe, persistent blood coagulation disorder with uncontrolled bleeding
- •Any congenital errors of amino acid metabolism
- •Uncontrolled hyperglycaemia despite insulin treatment
- •Known hypersensitivity to fish, egg, soybean proteins, peanut proteins, or to any of the active substances or excipients contained in SmofKabiven® extra Nitrogen or Olimel N9E
- •Known hypersensitivity to milk protein or to any other substance contained in Fresubin® Original
- •Treatment-refractory cardiopulmonary or metabolic instability showing persistent or progressive worsening despite increased interventions, including severe pulmonary oedema, severe cardiac insufficiency, myocardial infarction, acute phase of circulatory shock, severe sepsis, embolism, haemodynamic instability, metabolic or respiratory acidosis, hypotonic dehydration, or hyperosmolar coma
- •Severe renal dysfunction, defined as serum creatinine ≥2.0 times baseline or urine output <0.5 mL/kg/h for ≥12 hours (Acute Kidney Injury stage ≥2; [KDIGO 2012]), and blood urea nitrogen (BUN) exceeding 2 x upper limit of normal (ULN)
- •Severe liver failure with encephalopathy, including intoxication (e.g. paracetamol, death cap, golden chain) and/or liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma glutamyl transferase [GGT]) or bilirubin exceeding 5 x ULN
- •Oncologic disease with anticancer drug and/or radiation treatment incl. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) during this Trial up to and including Study Day 28
- •Preceding transplantation causal for acute critical illness
- •Hemophagocytic syndrome
- •Pregnancy or lactation
- •Receiving end-of-life-care
- •Pathologically altered blood pH (arterial pH <7.0), oxygen saturation (SaO2 <80%), or carbon dioxide concentration (PaCO2 ≥80 mm Hg)
- •Hyperlipidaemia or any disorder of lipid metabolism characterised by hypertriglyceridaemia (serum triglyceride levels >4 mmol/L [>350 mg/dL])
- •Treatment-refractory, clinically significant major abnormality in the serum concentration of any electrolyte (sodium, potassium, magnesium, total calcium, chloride, inorganic phosphate)
- •Administration of growth hormone including teduglutide within the previous 4 weeks before randomisation
- •Invasive devices and procedures influencing metabolism and organ perfusion, e.g. extracorporeal membrane oxygenation (ECMO), continuous renal replacement therapy (CRRT), molecular absorbent recycling system (MARS), intra-aortic balloon pump (IABP)
- •Receipt of the last dose of study drug in another interventional clinical trial within the previous 4 weeks before randomisation into this clinical trial
- •Previous inclusion in the present study
- •Any other known reason that may prevent a patient to take part in the study in accordance with local requirements
研究组 & 干预措施
SmofKabiven® extra Nitrogen
Experimental
Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
干预措施: SmofKabiven® extra Nitrogen (Drug)
Olimel N9E
Active Comparator
Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
干预措施: Olimel N9E (Drug)
结局指标
主要结局
Proportion of patients reaching ≥70% of the cumulative target for protein delivery from Study Day 2 through Study Day 6
时间窗: 5 days
The cumulative target for protein delivery is 6.75 g/kg over 5 Study Days (based on a daily target of 0.75 g/kg/day on Study Day 2 and 1.5 g/kg/day on Study Days 3 through 6); 70% of the cumulative target for protein delivery is 4.73 g/kg. The cumulative protein delivery is calculated as the cumulative intake of amino acids from study drug and protein from enteral or oral nutrition on Study Day 2 through Study Day 6.
次要结局
- Percentage of the cumulative target for protein delivery reached from Study Day 2 through Study Day 6(5 days)
- Mean cumulative protein delivery by parenteral, enteral, and oral nutrition from Study Day 2 through Study Day 6(5 days)
- Calculated mean cumulative protein deficit during the period from Study Day 2 through Study Day 6(5 days)
研究者
研究点 (3)
Loading locations...
相似试验
终止
4 期
Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer TherapyCancer-related MalnutritionNCT03355079Fresenius Kabi2
撤回
早期 1 期
S-Nitrosylation Therapy of COVID-19SARS-CoV2 InfectionCovid19NCT04528771James Reynolds24
招募中
1 期
S-Nitrosylation (SNO) Therapy During Autologous Blood TransfusionTransfusion Related ComplicationNCT03999229James Reynolds35
已完成
不适用
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic FunctionGlucose Metabolism DisordersNCT03151239Washington University School of Medicine25
已完成
2 期
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AMLAcute Myeloid LeukemiaNCT00373373University Hospital Muenster200